Soligenix (SNGX) Interest & Investment Income (2010 - 2020)
Soligenix's (SNGX) quarterly Interest & Investment Income came in at $486.0 in Q3 2020, down 98.69% YoY from $37007.0 in Q4 2019, and down 75.9% on a QoQ basis from $2017.0 in Q2 2020.
Soligenix (SNGX) Interest & Investment Income (2010 - 2020) Analysis & Trends
Soligenix (SNGX) has 10 years of Interest & Investment Income data on file, last reported at $486.0 in Q3 2020.
- Quarterly Interest & Investment Income fell 98.69% year-over-year to $486.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $47951.0 (down 72.34% YoY) and the FY2019 annual result came in at $148968.0, down 6.05% from the prior year.
- Interest & Investment Income retreated to $486.0 in Q3 2020, from $2017.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $56981.0 in Q3 2018 to a low of $486.0 in Q3 2020.
- A 5-year average of $21346.0 and a median of $16895.0 in 2018 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2018 — Interest & Investment Income surged 772.74% — and 2020, when it slumped 98.69%.
- Tracing SNGX's Interest & Investment Income over 5 years: stood at $2952.0 in 2016, then surged by 353.69% to $13393.0 in 2017, then jumped by 286.36% to $51745.0 in 2018, then sank by 54.58% to $23501.0 in 2019, then sank by 97.93% to $486.0 in 2020.
- The last three Interest & Investment Income figures came in at $486.0 (Q3 2020), $2017.0 (Q2 2020), and $21947.0 (Q1 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | 53,598.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 486.00 |
| Jun 30, 2020 | 2,017.00 |
| Mar 31, 2020 | 21,947.00 |
| Dec 31, 2019 | 23,501.00 |
| Sep 30, 2019 | 37,007.00 |
| Jun 30, 2019 | 39,851.00 |
| Mar 31, 2019 | 44,753.00 |
| Dec 31, 2018 | 51,745.00 |
| Sep 30, 2018 | 56,981.00 |
| Jun 30, 2018 | 32,948.00 |
| Mar 31, 2018 | 16,895.00 |
| Dec 31, 2017 | 13,393.00 |
| Sep 30, 2017 | 6,529.00 |
| Jun 30, 2017 | 5,231.00 |
| Mar 31, 2017 | 4,753.00 |
| Dec 31, 2016 | 2,952.00 |
| Sep 30, 2016 | 1,893.00 |
| Jun 30, 2014 | 322.00 |
| Mar 31, 2014 | 291.00 |
| Dec 31, 2013 | 522.00 |